Cargando…

P1576: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF V114 PNEUMOCOCCAL VACCINE IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS (PNEU-STEM)

Detalles Bibliográficos
Autores principales:	Wilck, M., Cornely, O., Ljungman, P., Cordonnier, C., Diego Velez, J., Dagan, R., Richmond, P., Chen, Q., Daus, C., Geddie, K., Sterling, T., Shekar, T., Musey, L., Buchwald, U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430870/ http://dx.doi.org/10.1097/01.HS9.0000849160.61177.a4

Ejemplares similares

P07 A Phase 3 randomized, double-blind, comparator-controlled study to evaluate safety, tolerability and immunogenicity of V114 pneumococcal vaccine in haematopoietic cell transplant recipients (PNEU-STEM)
por: Wilck, Marissa, et al.
Publicado: (2023)

A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)
por: Wilck, Marissa, et al.
Publicado: (2023)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
por: Quinn, Charles T., et al.
Publicado: (2022)

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
por: Severance, Randall, et al.
Publicado: (2021)

Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)
por: Hammitt, Laura L, et al.
Publicado: (2021)

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
por: Hammitt, Laura L., et al.
Publicado: (2023)

1184. A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)
por: Bili, Adroniki, et al.
Publicado: (2021)

1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors
por: Hammitt, Laura, et al.
Publicado: (2021)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV
por: Mohapi, Lerato, et al.
Publicado: (2022)

1174. Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU–PLAN)
por: Banniettis, Natalie, et al.
Publicado: (2021)

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
por: Wilck, Marissa, et al.
Publicado: (2023)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

P06 The 15-valent pneumococcal conjugate vaccine (PCV) V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
por: Platt, Heather L., et al.
Publicado: (2020)

Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies
por: Chapman, Timothy J., et al.
Publicado: (2023)

23. Did You Pneu?: Impact of an Adult Pneumococcal Immunization Campaign Across Independent Community Pharmacies
por: Faggioni, Mara, et al.
Publicado: (2020)

1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Buchwald, Ulrike, et al.
Publicado: (2018)

A Venetian "plague miracle" in 1464 and 1576.
por: Schupbach, W M
Publicado: (1976)

The PneuCarriage Project: A Multi-Centre Comparative Study to Identify the Best Serotyping Methods for Examining Pneumococcal Carriage in Vaccine Evaluation Studies
por: Satzke, Catherine, et al.
Publicado: (2015)

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
por: Cordonnier, Catherine, et al.
Publicado: (2015)

PReS13-SPK-1576: Unmeet needs in JIA treatment
por: Ruperto, N
Publicado: (2013)

Evaluation of a 15-valent Pneumococcal Conjugate Vaccine in an Adult Rhesus Macaque Immunogenicity Model
por: Xie, Jinfu, et al.
Publicado: (2017)

Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)
por: Ishihara, Yasunori, et al.
Publicado: (2023)

Girolamo Cardano (1501–1576). Arzt, Naturphilosoph, Mathematiker, Astronom und Traumdeuter
Publicado: (1978)

Catálogo del juzgado de testamentos, capellanías y obras pías, 1576-1854 /

Girolamo Cardano: 1501–1576 physician, natural philosopher, mathematician, astrologer, and interpreter of dreams
por: Fierz, Markus
Publicado: (1983)

Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly
por: Kawakami, Kenji, et al.
Publicado: (2018)

1576. Risk of Clinical Tuberculosis (TB) Among Patients with Latent TB Infection (LTBI) Who Undergo Allogeneic Hematopoietic-Cell Transplantation (HCT)
por: Kusztos, Amanda E, et al.
Publicado: (2018)

P1576: NOVEL APPROACHES TO MANAGEMENT OF COVID-19 IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Chudnova, Tatiana, et al.
Publicado: (2023)

Additive Manufacturing for Soft Robotics: Design and Fabrication of Airtight, Monolithic Bending PneuNets with Embedded Air Connectors
por: Stano, Gianni, et al.
Publicado: (2020)

La Real Hacienda de Nueva España, la Real Caja de México, 1576-1816 /
por: TePaske, John J. (John Jay), 1929-2007
Publicado: (1976)

LB1576. High Prevalence of Oral Treponema pallidum by PCR among US Adults with Early Syphilis
por: Dionne, Jodie, et al.
Publicado: (2022)

Identification of Four Secreted Aspartic Protease-Like Proteins Associated With Sophorolipids Synthesis in Starmerella bombicola CGMCC 1576
por: Liu, Jun, et al.
Publicado: (2021)

1576. Implementation of a Pharmacist-Driven Initiation of Antiretroviral Therapy in Patients Newly Diagnosed with Human Immunodeficiency Virus
por: Griffith, Kamron Amir, et al.
Publicado: (2023)

The incidence of ventilator-associated pneumonia using the PneuX System with or without elective endotracheal tube exchange: A pilot study
por: Doyle, Alex, et al.
Publicado: (2011)

PneuNet: deep learning for COVID-19 pneumonia diagnosis on chest X-ray image analysis using Vision Transformer
por: Wang, Tianmu, et al.
Publicado: (2023)

Reduced-Cost Production of Sophorolipids by Starmerella bombicola CGMCC1576 Grown on Cottonseed Molasses and Cottonseed Oil-Based Medium
por: Qin, Zehua, et al.
Publicado: (2023)

Lipidation of Pneumococcal Antigens Leads to Improved Immunogenicity and Protection
por: Voß, Franziska, et al.
Publicado: (2020)

Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled Trial
por: Pomat, William S., et al.
Publicado: (2013)

Immunogenicity of a 5‐dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cb95dd282ie3m6pgll2c4vu18a